From the Department of Psychiatry and Behavioral Sciences (J.A.B., M.A.B., P.M.D., L.W., B.H., K.B., S.H., A.L.B., A.S.), Duke University Medical Center, Durham, North Carolina; Department of Psychiatry and Behavioral Sciences (W.E.C.), Emory University, Atlanta, Georgia; Department of Medicine (R.W.), Duke University Medical Center, Durham, North Carolina; and Department of Medicine (A.H.), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Trial Registration. Clinical Trials Government Identifier: NCT-00331305.
Address correspondence and reprint requests to James Blumenthal, Department of Psychiatry and Behavioral Sciences, Box 3119, Duke University Medical Center, Durham, NC 7710. E-mail: [email protected]
Received for publication March 16, 2007; revision received May 14, 2007.
This research was supported by Grant MH 49679 (JAB) from the National Institutes of Health and National Institutes of Health Grant MO1-RR-30 from the National Center for Research Resources, Clinical Research Centers Program. Medication and matched placebo pills were provided by a grant from Pfizer Pharmaceuticals, Inc. Dr. Blumenthal previously received an investigator initiated research grant from Pfizer/Eisai for an unrelated study. Dr. Doraiswamy has received research grants and honoraria from several pharmaceutical companies and antidepressant manufacturers, including Pfizer, but does not own stock in these companies. Dr. Craighead owns stock in Novadel.